دورية أكاديمية
أعرض في EDS

Increased circulating IgG levels, myocardial immune cells and IgG deposits support a role for an immune response in pre- and end-stage heart failure.

التفاصيل البيبلوغرافية
العنوان: Increased circulating IgG levels, myocardial immune cells and IgG deposits support a role for an immune response in pre- and end-stage heart failure.
المؤلفون: van den Hoogen P; Laboratory of Experimental Cardiology, UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands., de Jager SCA; Laboratory of Experimental Cardiology, UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands., Huibers MMH; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.; Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands., Schoneveld AH; Laboratory of Clinical Chemistry & Haematology, ARCADIA, University Medical Center Utrecht, Utrecht, The Netherlands., Puspitasari YM; Laboratory of Experimental Cardiology, UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands.; Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland., Valstar GB; Laboratory of Experimental Cardiology, UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands., Oerlemans MIFJ; Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands., de Weger RA; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Doevendans PA; Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.; Heart and Lungs, Experimental Cardiology, Netherlands Heart Institute (NHI), Utrecht, The Netherlands.; Centraal Militair Hospitaal (CMH), Utrecht, The Netherlands., den Ruijter HM; Laboratory of Experimental Cardiology, UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands., Laman JD; Department of Biomedical Sciences of Cells and Systems (BSCS), University Medical Center Groningen, Groningen, The Netherlands., Vink A; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Sluijter JPG; Laboratory of Experimental Cardiology, UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands.
المصدر: Journal of cellular and molecular medicine [J Cell Mol Med] 2019 Nov; Vol. 23 (11), pp. 7505-7516. Date of Electronic Publication: 2019 Sep 26.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101083777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1582-4934 (Electronic) Linking ISSN: 15821838 NLM ISO Abbreviation: J Cell Mol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford, England : Wiley-Blackwell
Original Publication: Bucharest : "Carol Davila" University Press, 2000-
مواضيع طبية MeSH: Heart Failure/*blood , Heart Failure/*immunology , Immunoglobulin G/*blood , Immunoglobulin G/*immunology , Myocytes, Cardiac/*immunology, Case-Control Studies ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Myocardium/immunology ; Stroke Volume/immunology ; Ventricular Dysfunction, Left/blood ; Ventricular Dysfunction, Left/immunology
مستخلص: The chronic inflammatory response plays an important role in adverse cardiac remodelling and the development of heart failure (HF). There is also evidence that in the pathogenesis of several cardiovascular diseases, chronic inflammation is accompanied by antibody and complement deposits in the heart, suggestive of a true autoimmune response. However, the role of antibody-mediated immune responses in HF progression is less clear. We assessed whether immune cell infiltration and immunoglobulin levels are associated with HF type and disease stage, taking sex differences into account. We found IgG deposits and increased infiltration of immune cells in the affected myocardium of patients with end-stage HF with reduced ejection fraction (HFrEF, n = 20). Circulating levels of IgG1 and IgG3 were elevated in these patients. Furthermore, the percentage of transitional/regulatory B cells was decreased (from 6.9% to 2.4%) compared with healthy controls (n = 5). Similarly, increased levels of circulating IgG1 and IgG3 were observed in men with left ventricular diastolic dysfunction (LVDD, n = 5), possibly an early stage of HF with preserved EF (HFpEF). In conclusion, IgG deposits and infiltrates of immune cells are present in end-stage HFrEF. In addition, both LVDD patients and end-stage HFrEF patients show elevated levels of circulating IgG1 and IgG3, suggesting an antibody-mediated immune response upon cardiac remodelling, which in the early phase of remodelling appear to differ between men and women. These immunoglobulin subclasses might be used as marker for pre-stage HF and its progression. Future identification of auto-antigens might open possibilities for new therapeutic interventions.
(© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
References: Pharmacol Res. 2008 Aug;58(2):88-111. (PMID: 18620057)
J Am Coll Cardiol. 2007 Apr 24;49(16):1684-92. (PMID: 17448369)
Circ Heart Fail. 2017 Mar;10(3):e003688. (PMID: 28242779)
Am Heart J. 2006 Oct;152(4):712.e1-6. (PMID: 16996843)
Heart Fail Clin. 2005 Oct;1(3):449-56. (PMID: 17386867)
Cardiovasc Res. 2012 May 1;94(2):276-83. (PMID: 22266751)
J Autoimmun. 2003 Jun;20(4):345-50. (PMID: 12791320)
Expert Opin Ther Targets. 2005 Oct;9(5):963-73. (PMID: 16185152)
Heart. 2007 Sep;93(9):1137-46. (PMID: 17699180)
Autoimmunity. 2008 Sep;41(6):462-9. (PMID: 18781472)
J Am Coll Cardiol. 2002 Feb 20;39(4):646-52. (PMID: 11849864)
J Autoimmun. 2007 Aug;29(1):1-9. (PMID: 17582741)
Science. 2001 Jan 12;291(5502):319-22. (PMID: 11209085)
Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1358-H1367. (PMID: 30095974)
J Am Heart Assoc. 2017 Sep 7;6(9):. (PMID: 28882820)
Sci Rep. 2017 Jul 14;7(1):5400. (PMID: 28710441)
Circ Heart Fail. 2011 Jan;4(1):44-52. (PMID: 21075869)
Nat Rev Immunol. 2018 Dec;18(12):733-744. (PMID: 30228378)
Nat Rev Cardiol. 2014 May;11(5):255-65. (PMID: 24663091)
Front Immunol. 2014 Oct 20;5:520. (PMID: 25368619)
Am J Transl Res. 2013 Apr 19;5(3):327-35. (PMID: 23634243)
J Cell Mol Med. 2019 Nov;23(11):7505-7516. (PMID: 31557411)
Nat Med. 2003 Dec;9(12):1477-83. (PMID: 14595408)
Circulation. 2001 Apr 24;103(16):2055-9. (PMID: 11319194)
BMJ Open. 2019 Jun 5;9(6):e028408. (PMID: 31171553)
J Clin Apher. 2010;25(6):323-30. (PMID: 20872844)
J Exp Med. 2004 Jun 7;199(11):1577-84. (PMID: 15173206)
Eur J Heart Fail. 2016 Aug;18(8):891-975. (PMID: 27207191)
J Am Heart Assoc. 2016 Jan 14;5(1):. (PMID: 26769625)
BMC Cardiovasc Disord. 2014 May 11;14:67. (PMID: 24885051)
Am J Pathol. 2002 Aug;161(2):449-57. (PMID: 12163370)
Eur Heart J. 2014 Apr;35(16):1061-8. (PMID: 24375073)
Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. (PMID: 22227365)
Lancet. 2008 Jan 19;371(9608):228-36. (PMID: 18207018)
J Virol. 1995 Mar;69(3):1895-902. (PMID: 7853531)
J Exp Med. 2006 Jan 23;203(1):141-52. (PMID: 16390934)
N Engl J Med. 2017 Sep 21;377(12):1119-1131. (PMID: 28845751)
Circulation. 2000 Feb 1;101(4):385-91. (PMID: 10653829)
J Cardiol. 2017 Feb;69(2):409-416. (PMID: 27890513)
J Allergy Clin Immunol. 2016 Sep;138(3):654-665. (PMID: 27596706)
J Cardiovasc Pharmacol. 2014 Mar;63(3):185-95. (PMID: 24072174)
Eur Heart J. 2012 Oct;33(20):2551-67. (PMID: 22922414)
Neth Heart J. 2012 Aug;20(7-8):332-5. (PMID: 22618228)
Circ Heart Fail. 2015 Jul;8(4):776-87. (PMID: 26022677)
Circulation. 2001 May 8;103(18):2254-9. (PMID: 11342473)
Br Med J. 1964 Jul 18;2(5402):177. (PMID: 14150898)
N Engl J Med. 1995 Aug 3;333(5):269-75. (PMID: 7596370)
Front Neuroendocrinol. 2014 Aug;35(3):347-69. (PMID: 24793874)
Methodist Debakey Cardiovasc J. 2013 Jan-Mar;9(1):15-9. (PMID: 23519014)
فهرسة مساهمة: Keywords: B cells; autoantibodies; autoimmunity; biomarker; cardiomyopathy; inflammation
المشرفين على المادة: 0 (Immunoglobulin G)
تواريخ الأحداث: Date Created: 20190927 Date Completed: 20200910 Latest Revision: 20240721
رمز التحديث: 20240721
مُعرف محوري في PubMed: PMC6815814
DOI: 10.1111/jcmm.14619
PMID: 31557411
قاعدة البيانات: MEDLINE
الوصف
تدمد:1582-4934
DOI:10.1111/jcmm.14619